Insider Trading February 17, 2026

Avidbank Director Disposes $121,813 in Shares as Company Posts Mixed Q4 Results

Director Mike Rosinus sold 4,051 shares on Feb. 13, 2026; company delivered revenue beat but missed EPS in fiscal Q4 2025

By Leila Farooq AVBH
Avidbank Director Disposes $121,813 in Shares as Company Posts Mixed Q4 Results
AVBH

Avidbank Holdings director Mike Rosinus sold 4,051 shares of common stock on February 13, 2026, for $30.07 per share, totaling $121,813. After the sale he retains both direct and indirect holdings in the company. InvestingPro data shows the stock trading modestly above the sale price and near its 52-week high, while its valuation and near-term profitability forecasts present a mixed picture alongside recent quarterly results that beat revenue but missed earnings per share expectations.

Key Points

  • Director Mike Rosinus sold 4,051 shares on February 13, 2026, at $30.07 per share for a total of $121,813.
  • After the sale, Rosinus holds 188,198 shares indirectly and 16,680 shares directly.
  • Avidbank reported fiscal Q4 2025 EPS of $0.65 versus a $0.76 forecast, while revenue beat expectations at $26.78 million versus $25.97 million.

A director at Avidbank Holdings, Inc. (NASDAQ:AVBH) completed a notable insider sale on February 13, 2026, reporting the disposition of 4,051 shares of common stock. The shares were sold at $30.07 apiece, producing a gross transaction value of $121,813.

According to InvestingPro data, Avidbank's share price is trading at $30.73, a level modestly above the insider’s sale price and close to the company's 52-week high of $31.21. The proximity of market trading to that 52-week peak is highlighted alongside the director’s decision to sell.


Post-transaction holdings

Following the February sale, the director, Mike Rosinus, holds shares in two capacities: an indirect holding of 188,198 shares and a direct stake of 16,680 shares. Those balances reflect Rosinus’s continuing ownership exposure to Avidbank even after the recorded sale.


Valuation and analyst outlook

InvestingPro's analysis places Avidbank's market capitalization at $328.44 million and assesses the stock as appearing overvalued at current levels. Despite that view, analyst consensus remains favorable, with a "Strong Buy" rating and a reported high price target of $37.

InvestingPro also projects that the company’s net income will grow within the current year and notes a forecasted return to profitability in 2026.


Quarterly results - fiscal Q4 2025

Avidbank released fourth-quarter results for fiscal year 2025 that produced mixed signals. The company reported earnings per share of $0.65, below the $0.76 that analysts had forecast. At the same time, revenue of $26.78 million surpassed the expected $25.97 million.

The combination of an earnings miss alongside a revenue beat triggered a slight decline in the company’s stock during pre-market trading, per the reporting on those results. No recent analyst upgrades or downgrades were reported following the earnings release.


Takeaway

The insider sale, current market pricing near the 52-week high, InvestingPro's valuation assessment, the bullish analyst consensus, and the mixed quarterly metrics together present a nuanced picture of Avidbank’s near-term profile. Each of these elements is documented in public filings and InvestingPro reporting, and together they form the basis for investor evaluation of AVBH at present.

Risks

  • Earnings shortfall - The company missed EPS expectations for fiscal Q4 2025, which may raise concerns about near-term profitability for investors - impacts banking and financial markets.
  • Valuation concern - InvestingPro labels the company as appearing overvalued at current market capitalization of $328.44 million, which could affect investor appetite in the regional banking sector.
  • Profitability timeline uncertainty - Although InvestingPro forecasts a return to profitability in 2026, that projection introduces execution risk tied to the company meeting those expectations - relevant to financial performance assessments.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026